Jiao et al., 2015 - Google Patents
MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitusJiao et al., 2015
View HTML- Document ID
- 2010732639932522553
- Author
- Jiao Y
- Zhu M
- Mao X
- Long M
- Du X
- Wu Y
- Abudureyimu K
- Zhang C
- Wang Y
- Tao Y
- Luo X
- Li L
- Publication year
- Publication venue
- American Journal of Translational Research
External Links
Snippet
Aims: MicroRNAs play important roles in energy metabolism, insulin synthesis, insulin transport and the development of diabetes. This study aims to investigate the expression and effect of microRNA-130a in Uygur patients with type 2 diabetes mellitus (T2DM) …
- 208000001072 Type 2 Diabetes Mellitus 0 title abstract description 72
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10011835B2 (en) | miRNAs as novel therapeutic targets and diagnostic biomarkers for parkinson's disease | |
Jiao et al. | MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitus | |
Shi et al. | Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance | |
Zhao et al. | Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus | |
Meerson et al. | Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α | |
Raitoharju et al. | Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism—The Young Finns Study | |
Jiang et al. | Identification of several circulating microRNAs from a genome-wide circulating microRNA expression profile as potential biomarkers for impaired glucose metabolism in polycystic ovarian syndrome | |
Chen et al. | miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance | |
Chan et al. | Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis | |
Arner et al. | Adipose tissue microRNAs as regulators of CCL2 production in human obesity | |
Regmi et al. | Evaluation of serum microRNAs in patients with diabetic kidney disease: a nested case-controlled study and bioinformatics analysis | |
Vatandoost et al. | Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats | |
Huang et al. | MicroRNA expression profiling in diabetic GK rat model | |
Hu et al. | MicroRNA‑144‑3p may participate in the pathogenesis of preeclampsia by targeting Cox‑2 | |
Ezaz et al. | Differential associations of circulating MicroRNAs with pathogenic factors in NAFLD | |
Zhao et al. | A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer | |
Zhang et al. | The lncRNA RP11-142A22. 4 promotes adipogenesis by sponging miR-587 to modulate Wnt5β expression | |
US20190153446A1 (en) | Mir-149-3p and method for treating metabolic disease using the same | |
Wong et al. | Identification of novel microRNAs in the sheep heart and their regulation in heart failure | |
Du et al. | Comprehensive circular RNA profiling reveals that hsa_circ_0001368 is involved in growth hormone-secreting pituitary adenoma development | |
Yu et al. | Knockdown of plasmacytoma variant translocation 1 (PVT1) inhibits high glucose-induced proliferation and renal fibrosis in HRMCs by regulating miR-23b-3p/early growth response factor 1 (EGR1) | |
Abd El-Jawad et al. | The potential role of miR-27a and miR-320a in metabolic syndrome in obese Egyptian females | |
Chalmers et al. | Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by Metformin | |
Chen et al. | miR‑628 reduces prostate cancer proliferation and invasion via the FGFR2 signaling pathway | |
Nilsson et al. | Differential DNA methylation and expression of miRNAs in adipose tissue from twin pairs discordant for type 2 diabetes |